 Jessica Hellyer
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 13 | 2024 | 2660 | 1.970 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 8 | 2024 | 1186 | 1.900 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 6 | 2024 | 18 | 1.460 |
Why?
| | Thymus Neoplasms | 3 | 2020 | 30 | 1.390 |
Why?
| | NF-E2-Related Factor 2 | 5 | 2021 | 100 | 1.170 |
Why?
| | Neoplasms, Glandular and Epithelial | 2 | 2020 | 52 | 0.770 |
Why?
| | Anthracyclines | 2 | 2019 | 49 | 0.630 |
Why?
| | Thymoma | 1 | 2019 | 37 | 0.600 |
Why?
| | Cullin Proteins | 1 | 2019 | 14 | 0.590 |
Why?
| | Salvage Therapy | 2 | 2019 | 164 | 0.590 |
Why?
| | ErbB Receptors | 6 | 2021 | 632 | 0.580 |
Why?
| | Warfarin | 2 | 2016 | 173 | 0.560 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 427 | 0.560 |
Why?
| | Mutation | 6 | 2024 | 4081 | 0.530 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 437 | 0.500 |
Why?
| | Atrial Fibrillation | 2 | 2016 | 555 | 0.390 |
Why?
| | Autonomic Nervous System | 1 | 2013 | 81 | 0.390 |
Why?
| | Anticoagulants | 2 | 2016 | 729 | 0.360 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 2201 | 0.340 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2024 | 881 | 0.340 |
Why?
| | Hemorrhage | 1 | 2016 | 813 | 0.340 |
Why?
| | Stroke | 2 | 2016 | 1262 | 0.320 |
Why?
| | Heart | 1 | 2013 | 626 | 0.300 |
Why?
| | Antibodies, Monoclonal | 4 | 2024 | 1505 | 0.260 |
Why?
| | Neoplasm Staging | 3 | 2020 | 1465 | 0.250 |
Why?
| | Blood Pressure | 1 | 2013 | 1766 | 0.250 |
Why?
| | Genes, Tumor Suppressor | 2 | 2024 | 85 | 0.220 |
Why?
| | Retrospective Studies | 7 | 2022 | 17149 | 0.210 |
Why?
| | CTLA-4 Antigen | 1 | 2024 | 105 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 2 | 2021 | 971 | 0.200 |
Why?
| | Prospective Studies | 3 | 2021 | 7994 | 0.200 |
Why?
| | Stellate Ganglion | 2 | 2013 | 8 | 0.200 |
Why?
| | Vagus Nerve | 2 | 2013 | 92 | 0.190 |
Why?
| | Prognosis | 3 | 2019 | 4312 | 0.180 |
Why?
| | Consolidation Chemotherapy | 1 | 2021 | 11 | 0.180 |
Why?
| | Acrylamides | 1 | 2021 | 73 | 0.160 |
Why?
| | Humans | 17 | 2024 | 144671 | 0.160 |
Why?
| | Exons | 1 | 2021 | 362 | 0.160 |
Why?
| | Aniline Compounds | 1 | 2021 | 121 | 0.160 |
Why?
| | Everolimus | 1 | 2020 | 112 | 0.160 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2019 | 20 | 0.150 |
Why?
| | Mesothelioma | 1 | 2019 | 50 | 0.140 |
Why?
| | Treatment Failure | 1 | 2019 | 365 | 0.130 |
Why?
| | Survival Rate | 2 | 2019 | 2089 | 0.130 |
Why?
| | Homologous Recombination | 1 | 2017 | 37 | 0.130 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2019 | 121 | 0.130 |
Why?
| | BRCA2 Protein | 1 | 2017 | 68 | 0.130 |
Why?
| | BRCA1 Protein | 1 | 2017 | 82 | 0.130 |
Why?
| | International Normalized Ratio | 1 | 2016 | 52 | 0.120 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 691 | 0.120 |
Why?
| | Precision Medicine | 1 | 2020 | 454 | 0.110 |
Why?
| | Dogs | 2 | 2013 | 438 | 0.110 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8284 | 0.110 |
Why?
| | Patient Selection | 1 | 2019 | 727 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1961 | 0.110 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2017 | 217 | 0.110 |
Why?
| | Immunotherapy | 1 | 2019 | 662 | 0.100 |
Why?
| | Adrenergic beta-2 Receptor Antagonists | 1 | 2013 | 1 | 0.100 |
Why?
| | Hypotension, Orthostatic | 1 | 2013 | 11 | 0.100 |
Why?
| | Middle Aged | 5 | 2019 | 35971 | 0.100 |
Why?
| | Male | 8 | 2024 | 72431 | 0.100 |
Why?
| | Female | 9 | 2024 | 78304 | 0.100 |
Why?
| | Adrenergic Fibers | 1 | 2012 | 6 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1327 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5414 | 0.090 |
Why?
| | Aged | 5 | 2019 | 25955 | 0.090 |
Why?
| | Electric Stimulation | 1 | 2012 | 277 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 657 | 0.080 |
Why?
| | Heart Rate | 1 | 2012 | 853 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2019 | 11735 | 0.060 |
Why?
| | Animals | 6 | 2024 | 37948 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2024 | 116 | 0.050 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2024 | 161 | 0.050 |
Why?
| | Tumor Suppressor Proteins | 1 | 2024 | 319 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 242 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 10796 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 230 | 0.040 |
Why?
| | Mice | 3 | 2024 | 18261 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 729 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 239 | 0.040 |
Why?
| | Etoposide | 1 | 2019 | 168 | 0.040 |
Why?
| | Carboplatin | 1 | 2019 | 161 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 2019 | 74 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 990 | 0.030 |
Why?
| | Paclitaxel | 1 | 2019 | 256 | 0.030 |
Why?
| | Bridged-Ring Compounds | 1 | 2017 | 31 | 0.030 |
Why?
| | Taxoids | 1 | 2017 | 116 | 0.030 |
Why?
| | Cisplatin | 1 | 2019 | 339 | 0.030 |
Why?
| | Pyrimidines | 1 | 2021 | 519 | 0.030 |
Why?
| | Indoles | 1 | 2021 | 504 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1984 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1136 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 650 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 464 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1145 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1056 | 0.030 |
Why?
| | Cervical Plexus | 1 | 2012 | 3 | 0.020 |
Why?
| | Choline O-Acetyltransferase | 1 | 2012 | 26 | 0.020 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2012 | 72 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2012 | 184 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3109 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2019 | 0.020 |
Why?
| | Sympathetic Nervous System | 1 | 2012 | 180 | 0.020 |
Why?
| | Reference Values | 1 | 2012 | 794 | 0.020 |
Why?
| | Models, Animal | 1 | 2012 | 393 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4539 | 0.020 |
Why?
| | Brain | 1 | 2022 | 2934 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3888 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1705 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5967 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1995 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 7140 | 0.010 |
Why?
| | Adult | 1 | 2017 | 40489 | 0.010 |
Why?
|
|
Hellyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|